BioSpace News Archive

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 10,000 shares of common stock.

Seres Therapeutics, Inc. announced that on March 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 15,500 shares of its common stock to three new employees, consisting of stock options to purchase an aggregate of 9,250 shares of common stock and restricted stock units, covering an aggregate of 6,250 shares of its common stock.

Quest Diagnostics announced that its Board of Directors elected James E. Davis, the company’s Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase 33,000 shares of its common stock with an exercise price of $5.43 per share, which is equal to the closing price of Kezar’s common stock on March 2, 2023, the grant date of the awards.

Aadi Bioscience, Inc. announced that Brendan Delaney has resigned for personal reasons from his position as Chief Executive Officer, President, and member of the Board of Directors of the Company.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference.

DermTech, Inc. announced that management is scheduled to present at the following investor conferences during March 2023.

Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results from a Phase I trial in solid tumor patients.

Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data for its lead oncogenic driver candidate targeting KRAS G12V, AFNT-111, will be presented at the AACR Special Conference: Targeting Ras.

PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that it will host a business update conference call and webcast on Wednesday, March 15, 2023, at 8:30 AM EST.